Полиморфизм генов р53, XRCC1 и ССR5 у больных неходжкинскими злокачественными лимфомами
Диссертация
Ряд авторов указывают на то, что одни и те же аллели полиморфных ло-кусов генов р53, XRCC1 и CCR5 могут иметь как проонкогенный, так и защитный эффект, в зависимости от этнической принадлежности популяции, типа ткани, из которой развивается' опухоль и воздействия вредных факторов внешней среды. По этой причине данные литературы по вопросу о роли полиморфных вариантов ДНК в онкологическом риске… Читать ещё >
Содержание
- Глава 1. ОБЗОР ЛИТЕРАТУРЫ
- 1. 1. Современные представления о неходжкинских злокачественных лим-фомах
- 1. 2. Генетические основы опухолевой прогрессии
- 1. 3. Роль р53 в онкогенезе
- 1. 4. Гены семейства XRCC
- 1. 5. Роль хемокинов и хемокиновых рецепторов при опухолях
- Глава 2. МАТЕРИАЛ И МЕТОДЫ ИССЛЕДОВАНИЯ
- 2. 1. Общая характеристика группы обследованных больных
- 2. 2. Методы клинического, лабораторного и инструментального исследования
- 2. 3. Специальные методы исследования
- 2. 3. 1. Выделение ДНК из лейкоцитов цельной венозной крови больных лим-фомами'
- 2. 3. 2. Оценка полиморфизмов с помощью аллель-специфичной ПЦР и ПЦР-ПДРФ-анализа
- 2. 4. Статистические методы исследования,
- РЕЗУЛЬТАТЫ СОБСТВЕННОГО ИССЛЕДОВАНИЯ
- Глава 3. ЧАСТОТА ПОЛИМОРФИЗМОВ ГЕНОВ Р53, CCR5 И XRCC1 У БОЛЬНЫХ 11ЕХОДЖКИНСКИМИ ЗЛОКАЧЕСТВЕННЫМИ ЛИМФОМАМИ
- Глава 4. ПОЛИМОРФИЗМЫ ГЕНОВ Р53, CCR5 И XRCC1 У БОЛЬНЫХ ИНДОЛЕНТНЫМИ И АГРЕССИВНЫМИ ЛИМФОМАМИ
- Глава 5. ОСОБЕННОСТИ КЛИНИЧЕСКОГО ТЕЧЕНИЯ НЕХОДЖКИНСКИХ ЗЛОКАЧЕСТВЕННЫХ ЛИМФОМ У ПАЦИЕНТОВ С
- ПОЛИМОРФИЗМАМИ ГЕНОВ Р53, CCR5 HXRCCl
- Глава 6. ОБСУЖДЕНИЕ РЕЗУЛЬТАТОВ СОБСТВЕННОГО ИССЛЕДОВАНИЯ
Список литературы
- Агеенко А. И. Комплексная омелотерапия в иммунореабилитации больных раком и новая общая теория канцерогенеза / А. И. Агеенко, И. С. Ролик // Натуротерапия и гомеопатия. 2006. — № 1. — С. 9−13.
- Акмаев И. Г. От нейроэндокринологии к нейроиммуноэндокриноло-гии / И. Г. Акмаев, В. В. Гриневич // Бюл. эксперим. биол. и мед. 2001. —Т. 131, № 1.-С. 22−33.
- Баранов В. С. Гены предрасположенности и генетический паспорт / В. С. Баранов, М. В. Асеев, Е. В. Баранова // Пророда. 1999. — № 3. — С. 1925.
- Барышников А. Ю. Программированная клеточная смерть (апоптоз) / А. Ю. Барышников // Клиническая онкогематология / под ред. М. А. Волковой. М.: Медицина, 2001. — С. 36−42.
- Бочков Н. П. Клиническая генетика: учебник / Н. П. Бочков. 2-е изд., перераб. и доп. — М.: ГЭОТАР-МЕД, 2002. — 448 с.
- Вебер Д. Упорядоченная биохимическая программа экспрессии гена в раковых клетках / Д. Вебер // Биохимия. 2001. — Т66, № 8. — С. 1438−1449.
- Воробьев А. И. Руководство по гематологии: в 3 т. / под ред. А. И. Воробьева. 3-е изд., перераб. и доп. — М.: Ньюдиамед, 2003. — Т. 2. — 280 с.
- Генотипы и гаплотипы гена-онкосупрессора р53: ассоциация с продолжительностью жизни у русских Новосибирской области / Н. А. Сметан-никова и др. // Сибирский онкологический журнал: Научно-практическое издание.-2006.-№ 2.-С. 37−41.
- Горбунова В. Н. Введение в молекулярную диагностику и генотера-пию наследственных заболеваний / В. Н. Горбунова, В. С. Баранов СПб.: СпецЛит, 1997. — 287с.
- Зависимость эффекта лечения УФ-облучением у больных псориазом от Arg/Pro полиморфизма гена р53 / В. Р. Хайрутдинов и др. // Вестник дерматологии и венерологии. 2005. — № 2. — С. 21—24.
- Залетаев Д. В. ДНК-диагностика в онкологии / Д. В. Залетаев // Молекулярная биология. 2000. — Т. 34. — С. 578−589.
- Залетаев Д. В. Современные подходы в ДНК-диагностике онкозаболеваний / Д. В. Залетаев, М. В. Немцова // Молекулярно-биологические технологии в медицинской практике. 2007. — № 11. — С. 22−23.
- Зборовска И. Б. Супрессоры опухолевого роста (антионкогены), механизмы действия, участие в развитии гемобластозов / И. Б. Зборовска // Клиническая онкогематология / под ред. М. А. Волковой. М.: Медицина, 2001.-С. 29−34.
- Имянитов Е. Н. Наследственная предрасположенность к онкологическим заболеваниям / Е. Н. Имянитов // Молекулярно-биологические технологии в медицинской практике. 2007. — № 11. — С. 12−15.
- Ковынев И. Б. Особенности частоты и структуры неходжкинских злокачественных лимфом в Новосибирске, НСО и городах Сибирского федерального округа / И. Б. Ковынев, М. И. Лосева, Т. И. Поспелова // Бюллетень СО РАМН. 2006. — № 4 (122). — С. 175−181.
- Концентрация про- и противовоспалительных цитокинов как возможный фактор прогноза у больных гемобластозами / Скворцова Н. В. и др. // Медицина и образование в XXI веке: материалы конференции. Новосибирск, 2005. — С. 345.
- Ляхович В. В. Молекулярно-генетические подходы в современной онкологии реальность и перспективы / В. В. Ляхович, С. П. Коваленко // Молекулярно-биологические технологии в медицинской практике. — 2007, № 11.-С. 3−7.
- Механизмы опухолевой прогрессии: роль генов апоптоза и цитокинов / Чердынцева Н. В. и др. // Молекулярно-биологические технологии в медицинской практике. 2007, № 11. — С. 28−39.
- Мушкамбаров Н. Н. Апоптоз. Генетическая природа онкогенеза / Н. Н. Мушкамбаров, С. Л. Кузнецова // Молекулярная биология: учебное пособие для студентов медицинскиз вузов. — М.: ООО Мед. информ. агентство, 2003.-С. 443−506.
- Основы опухолевой прогрессии гемобластозов / Т. И. Поспелова и др. // Бюлл. СО РАМН. 2004. — № 2. — С. 73−76.
- Поддубная И.В. Неходжкинские лимфомы / И. В. Поддубная // Клиническая онкогематология: руководство для врачей. под ред. М. А. Волковой. -М.: Медицина, 2001. — С. 336−376.
- Полиморфизм гена хемокинового рецептора CCR5 и его взаимосвязь с опухолевыми маркерами у больных раком легкого / М. В. Флеминг и др. // Российский биотерапевтический журнал: теоретический и научно-практический журнал. 2004. — № 2. — С. 39.
- Полиморфизм гена хемокинового рецептора CCR5 у больных рассеянным склерозом в Сибирском регионе / Ю. Ю. Орлова и др. // Бюллетень Сибирской медицины. 2006. — № 3. — С. 98−104.
- Распространенность делеции 32 п.н. в гене рецептора хемокинов CCR5 в популяциях Волго-Уральского региона / А. Р. Галеева и др. // Генетика. 1998. — Т. 34, № 8. — С. 1160−1162.
- Сейц Н. Ф. Молекулярная онкология: руководство для врачей / Н. Ф. Сейц, П. Г. Князев. Д.: Медицина, 1986. — 352 с.
- Скворцова Н. В. Цитокиновый профиль больных лимфомами в динамике полихимиотерапии : дис.. канд. мед. наук: 14.00.29 / Н. В. Скворцова- Новое, госуд. мед. унив. Новосибирск, 2005. — 272 с.
- Сравнительный анализ функционального полиморфизма генов CCR5, Р53, GSTT1 и GSTM1 у больных раком легкого и атопической бронхиальной астмой / М. В. Флеминг и др. // Аллергология и иммунология. -2006.-№ 7 (3). -С. 311.
- Татосян А. Г. Механизмы активации онкогенов / А. Г. Татосян, Э. Ш. Зуева // Клиническая онкогематология: руководство для врачей. — под ред. М. А. Волковой. -М.: Медицина, 2001. С. 22−28.
- Ульрих Е. А. Редкие формы рака тела матки / Е. А. Ульрих, Э. JI. Нейштадт // Практическая онкология. 2004. — Т. 5, № 1. — С. 68−76.
- Функциональный полиморфизм генов онкосупрессорного белка р53 и хемоконового рецептора CCR5 у больных раком легкого и бронхиальной астмой // Медицинская иммунология. 2005. — Т. 7, № 2−3. — С. 211−212.
- Функциональный полиморфизм генов р53 и CCR5 у долгожителей Сибирского региона / М. А. Сметанникова и др. // Вестник Российской академии медицинских наук. 2004. — № 11. — С. 25−8.
- Цитокины в патогенезе злокачественных новообразований / Н. В. Чердынцева и др. // Цитокины и воспаление. 2005. — № 2. — С. 103.
- Ярилин А. А. Основы иммунологии : учебник / А. А. Ярилин. М.: Медицина, 1999. — С. 608.
- Aberrations of the p 53 gene in roentgenographically occult squamous cell carcinoma of the lung / C. Endoh et al. // Kyobu Geka. 1996. — Vol. 49. -P. 990−3.
- A cell cycle-specific requirement for the XRCC1 BRCTII domain during mammalian DNA strand break repair / R. M. Taylor et al. // Cell. Biol. 2000. -Vol. 20.-P. 735−740.
- A chemokine receptor antagonist inhibits experimental breast tumor growth/ S. C. Robinson et al.// Cancer Res.-2003.-Vol. 63.-P. 8360−5.
- A Chinese-hamster ovary cell mutant (EM-C11) with sensitivity to simple alkylating agents and a very high level of sister chromatid exchanges / M. Z. Zdzienicka et al. // Mutagenesis 1992. — Vol. 7. — P. 265−269.
- Acommon polymorphism acts as an intragenic modifier of mutant p53 behaviour / M. C. Marin et al. // Nat. Genet. 2000, May. — Vol. 25, № 1. — P. 47−54.
- A dual tropic primary HIV-1 isolate that uses fiisin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion co-factors / B. J. Doranz et al. // Cell 1996. — Vol. 85. — P. 1149−1158.
- Age-associated Increase of Codon 72 Arginine p53 Frequency in Gastric Cardia and Non-Cardia Adenocarcinoma / Z. W. Zhang et al. // Clinical Cancer Research 2003, Jun. — Vol. 9.-P. 2151−2156.
- A haplotype containing the p53 polymorphisms Insl6bp and Arg72Pro modifies cancer risk in BRCA2 mutation carriers / A. Osorio et al. // Hum. Genet. 2006, Mar. — Vol. 27, № 3. — P. 242−8.
- Allelic frequency of a p53 polymorphism in human lung cancer / A. Weston et al. // Cancer Epidemiol. Biomarkers Prev. 1992, Sep-Oct. — Vol. 1, № 6. -P. 481−3.
- Allelic frequency of p53 gene codon 72 polymorphism in urologic cancers / W. Wu et al. // Jpn. J. Cancer Res. 1995. — Vol. 86. — P. 730−736.
- Alterations in exon 4 of the p53 gene in gastric carcinoma / T. Shepherd et al. // Gastroenterology. 2000. — V. 118. — P. 1039−1044.
- Amino acid substitution variants of APE1 and XRCC1 genes associated with ionizing radiation sensitivity / J. J. Hu et al. // Carcinogenesis. 2001. -Vol. 22.-P. 917−922.
- Amodel for antagonistic pleiotropic gene action for mortality and advanced age / B. Toupance et al. // Am. J. Hum. Genet. 1998, Jun. — Vol. 62, № 2.-P. 1525−34.
- Amplification of a gene encoding a p53-associated protein in human sarcomas / J. D. Oliner et al. // Nature 1992. — Vol. 358. — P. 80−3.
- Analysis of human papillomavirus type 16 E6 variants in relation to p53 codon 72 polymorphism genotypes in cervical carcinogenesis / M. van Duin et al. // J. Gen. Virol. -2000. Vol. 81. — P. 317−25.
- Analysis of p53 and mdm-2 expression in 18 patients with Sezary syndrome / D. I. Marks et al. // Br. J. Haematol. 1996, Mar. — Vol. 92, № 4. — P. 890−9.
- Analysis of the anti-p53 antibody response in cancer patients / S. Labresque et al. // Cancer Res. 1993, Aug. — Vol. 53, № 15. — P. 3468−71.
- A novel germ line p53 mutation in intron 6 in diverse childhood malignancies / S. Avigad et al. // Oncogene. 1997, Apr. — Vol. 14, № 13. — P. 1541−5.
- A novel germ-line mutation in the noncoding region of the p53 gene in a Li-Fraumeni family / D. Barel et al. // Cancer Genet. Cytogenet. 1998, May. -Vol. 103, № l.-P. 1−6.
- A novel polymorphism in intron 6 of the human p53 gene: a possible association with cancer predisposition and susceptibility / S. Peller et al. // DNA Cell Biol.- 1995, Dec. Vol. 14, № 12. — P. 983−90.
- A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking inhepatitis В carriers / M. W. Yu et al. // Hepatology. 1999, Mar. — Vol. 29, № 3. -P. 697−702.
- A role for chemokine receptor transactivation in growth factor signaling / E. Mira et al. // EMBO Rep. 2001. — Vol. 2. — P. 151−156.
- Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma / R. D. Leek et al. // Cancer Res. 1996. — Vol. 56.-P. 4625−9.
- Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer / X. E. Huang et al. // Breast Cancer. 2003. — Vol. 10, № 4. — P. 307−11.
- Association of specific genotype and haplotype of p53 gene with cervical cancer in India / S. Mitra et al. // J. Clin. Pathol. 2005, Jan. — Vol. 58, № 1. — P. 26−31.
- Association of the DNA repair gene XPD Asp312Asn polymorphism with p53 gene mutations in tobacco-related non-small cell lung cancer / W. M. Gao et al. // Carcinogenesis. -2003, Oct. Vol. 24, № 10. — P. 1671−6.
- A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins / P. Bore et al. // Faseb J. 1997, Jan. — Vol. 11, № 1. -P. 68−76.
- A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA / F. Gemignani et al. // Oncogene. -2004, Mar. Vol. 23, № 10. — P. 1954−6.
- A variation in the structure of the protein-coding region of the human p53 gene / V. L. Buchman et al. // Gene. 1988, Oct. — Vol. 70, № 2. — P. 245−52.
- Bcl-2 protein expression and p53 gene mutation in chronic lymphocytic leukemia: correlation with in vitro sensitivity to chlorambucil and purine analogs / F. Morabito et al. // Haematologica. 1997, Jan-Feb. — Vol. 82, № 1. — p. 16−20.
- Bcl-6 p53 mutations in lymphomas carrying the bcl-2/Jh rearrangement / M. Bellido et al. // Haematologica. 2002, Sep. — Vol. 87, № 9. — P. 908−17.
- Beckman К. B. Oxidative decay of DNA / К. B. Beckman, B. N. Ames // J. Biol. Chem. 1997. — Vol. 272. — P. 19 633−19 636.
- Bhattacharya P. Proline homozygosity in codon 72 of p53: a risk genotype for human papillomavirus related cervical cancer in Indian women / P. Bhat-tachaiya, C. Duttagupta, S. Sengupta // Cancer Lett. 2002. — Vol. 188. — P. 20 711.
- Bingle L. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies / L. Bingle, N. J. Brown, С. E. Lewis // J. Pathol. 2002. — Vol. 196. — P. 254−65.
- Birgander R. p53 polymorphisms and haplotypes in lung cancer / R. Bir-gander, A. Sjalander, A. Rannug // Carcinogenesis. 1995. — Vol. 16. — P. 22 332 236.
- Bone marrow transplantation / T. Pilip et al. // Bone marrow transplantation. 1998. — Vol. 21. — P. 179.
- Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival / J. Tommiska et al. // Clin. Cancer Res. 2005, Jul. — Vol. 11, № 14.-P. 5098−103.
- Brimnes M. K. Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma / M. K. Brimnes, I. M. Svane, H. E. Johnsen // Clin. Exp. Immunol. 2006, Apr. — Vol. 144, № 1. — P. 76−84.
- Caldecott K. W. Mammalian DNA single-strand break repair: an X-rayted affair / K. W. Caldecott // Bioessays. 2001. — № 23. — P. 447−455.
- Cancer Statistics, 2006 / A. Jemal et al. // Cancer Journal for Clinicians. 2006, May. — Vol. 56. — P. 106−130.
- Casse С. The XRCC1 codon 399 Gin allele is associated with adenine to guanine p53 mutations in non-small cell lung cancer / C. Casse, Y. C. Hu, S. A. Ahrendt // Mutat Res. 2003, Jul. — Vol. 528, № 1−2. — P. 19−27.
- CC chemokine receptor 5 and renal-transplant survival / M. Fischereder et al. // Lancet.-2001.-Vol. 357.-P. 1758−1761.
- C-C Chemokine Receptor 5 on Stromal Cells Promotes Pulmonary Metastasis / H. D. van Deventer et al. // Cancer Research. 2005, Apr. — Vol. 65. -P. 3374−3379.
- CC chemokines and the receptors CCR3 and CCR5 are differentially expressed in the nonneoplastic leukocytic infiltrates of Hodgkin disease / C. Buri et al.//Blood.-2001, Mar.-Vol. 97, № 6. -P. 1543−1548.
- CC CKR5: A RANTES, MIP-1 alpha, MlP-lbeta receptor as a fusion co-factor for macrophage-tropic HIV-1 / G. Alkhatib et al. // Science. 1996. -Vol. 272.-P. 1955−1958.
- CCR5 delta32, matrix metalloproteinase-9 and disease activity in multiple sclerosis / F. Sellebjerg et al. // J. Neuroimmunol. 2000. — № 102. — P. 98 106.
- CCR5 expression influences the progression of human breast cancer in a p53-dependent manner / S. Manes et al. // J. Exp. Med. 2003, Nov. — Vol. 9. -P. 1381−9.
- CCR5 is characteristic of Thl lymphocytes / P Loetscher et al. // Nature. 1998. — Vol. 391. — p. 344−345.
- CCR5-binding chemokines modulate CXCL12 (SDF-l)-induced responses of progenitor В cells in human bone marrow through heterologous desen-sitization of the CXCR4 chemokine receptor / M. Honczarenko et al. // Blood. -2002, Oct. Vol. 100, № 7. — P. 2321−9.
- Cells deficient in DNA polymerase beta are hypersensitive to alkylating agent-induced apoptosis and chromosomal breakage / K. Ochs et al. // Cancer Res.-1999.-Vol. 59.-P. 1544−1551.
- Characterization of a frequent polymorphism in the coding sequence of the Tp53 gene in colonic cancer patients and a control population / S. Olschwang et al. // Hum. Genet. 1991. — Vol. 86. — P. 369−370.
- Cheeson B. D. ISH-ENA Combined Haematology Congress, Educational Programm Book / B. D. Cheeson // ISH-ENA Combined Haematology Congress, Educational Programm Book. 1998. — P. 128−135.
- Chemokine and Chemokine Receptor Gene Variants and Risk of Non-Hodgkin's Lymphoma in Human Immunodeficiency Virus-1-Infected Individuals / C. S. Rabkin et al. //Blood. 1999, Mar. — Vol. 93, № 6. — P. 1838−1842.
- Chemokine receptor CCR2/CCR5 polymorphism in Spanish patients with systemic lupus erythematosus / F. Aguilar et al. // J. Reumatol. 2003, Aug. — Vol. 30, № 8. — P. 1770−4.
- Chemokine receptor CCR5: polymorphism at protein level / S. Suzuki et al. // Biochem. Biophys. Res. Commun. 2002, Aug. — Vol. 296, № 2. — P. 477−483.
- Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas / S. Baker et al. // Science. 1989. — Vol. 244. — P. 217−21.
- Clinical effects of tumor-associated macrophages and dendritic cells on renal cell carcinoma / I. Hamada et al. // Anticancer Res. 2002. — Vol. 22. — P. 4281−4.
- Cloning and functional expression of CC CKR5, a human monocyte CC chemokine receptor selective for MIP-1 alpha, MlP-lbeta and RANTES / C. Com-badiere etal. //J. Leukoc. Biol. 1996.-Vol. 60.-P. 147−152.
- Codon-72 polymorphism of the Tp53 gene / S. Ara et al. // Nucleic. Acids. Res. 1990. — Vol. 18. — P. 4961.
- Contribution of epigenetic risk factors but not p53 codon 72 polymorphism to the development of cervical cancer in northeastern Thailand / W. Set-theetham-Ishida et al. // Cancer Lett. 2004. — Vol. 210. — P. 205−11.
- Correlation between human papillomavirus-associated cervical cancer and p53 codon 72 arginine/proline polymorphism / R. Tachezy et al. // Hum. Genet. 1999. — Vol. 105. — P. 564−6.
- Correlation of genetic polymorphisms in DNA repair genes ADPRT and XRCC1 to risk of gastric cancer / Z. Zhang et al. // Ai Zheng. 2006, Jan. — Vol. 25, № 1.-P. 7−10. 4
- Correlation of the mutation of p53 gene and the polymorphism at codon 72 in smoking-related non-small cell lung cancer patients / M. Murata et al. // Int. J. Oncol. 1998, Mar. — Vol. 12, № 3. — P. 577−81.
- Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer / Y. Niwa et al. // Clin. Cancer Res. -2001.-Vol. 7.-P. 285−289.
- Cutaneous squamous cell carcinoma and p53 codon 72 polymorphism: a need for screening? / M. T. Bastiaens et al. // Mol. Carcinog. 2001, Jan/ - Vol. 30, № l.-P. 56−61.
- CXCR4 and CCR5 on human thymocytes: Biological function and role in HIV-l infection / M. B. Zaitseva et al. // J. Immunol. 1998. — Vol. 161. — P. 3103−3113.
- Cyster J. G. Chemokines and Cell Migration in Secondary Lymphoid Organs / J. G. Cyster // Science. 1999, Dec. — Vol. 286, № 5447. — P. 2098 -2102.
- Dendritic cells express multiple chemokine receptors used as corecep-tors for HIV entry / A. Rubbert et al. // J. Immunol. 1998. — Vol. 160. — P. 3933−3941.
- Detection of BCL-6 rearrangements and p53 mutations in Malt-lymphomas / G. Gaidano et al. // Am. J. Hematol. 1997, Dec. — Vol. 56, № 4. -P. 206−13.
- Detection of serum anti p53 antibodies and their correlation with p53 mutations in myelodysplastic syndromes and acute myeloid leukemia / C. Preud-homme et al. // Leukemia. 1994. — Vol. 8. — P. 1589.
- Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation / S. F. Winter et al. // Cancer Res. -1992, Aug. Vol. 52, № 15. — P. 4168−74.
- Dias S. The role of CXC chemokines in the regulation of tumor angio-genesis / S. Dias, M. Choy, S. Rafii // Cancer Invest. 2001. — Vol. 19. — P. 7328.
- Disruption of p53 in human cancer cells alters the responses to therapeutic agents / F. Bunz et al. // J. Clin. Invest. 1999. — Vol. 104. — P. 263−9.
- Distribution of the 32 bp deletion in the CCR5 chemokine receptor gene in populations of the Volga-Ural region / A. R. Galeeva et ah. // Genetika. -1998, Aug. Vol. 34, № 8. — P. 1160−2.
- DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladder cancer in a case-control study / G. Matullo et al. // Int. J. Cancer. -2001. -Vol. 92. P. 562−567.
- DNA repair gene XRCC1 polymorphisms, smoking, and bladder cancer risk / M. C. Stern et al. // Cancer Epidemiol. Biomarkers Prev. 2001. — Vol. 10. -P. 125−131.
- DNA repair gene XRCC1 polymorphisms, smoking, and esophageal cancer risk / H. P. Yu et al. // Cancer Detect. Prev. 2004. — Vol. 28, № 3. — P. 194−9.
- DNA Sequence Variants of p53: Cancer and Aging / Y. Sun et al. // Am J. Hum. Genet. 1999, Dec. — Vol. 65, № 6. — P. 1779−1782.
- Domain specific interaction in the XRCC1-DNA polymerase complex / A. Marintchev et al. // Nucleic Acids Res. 2000, May. — Vol 28, № 10. — P. 2049−2059.
- Donor CCR5 Delta32 polymorphism and outcome following cardiac transplantation / J. E. Fildes et al. // Transplant. Proc. 2005, Jun. — Vol. 37, № 5.-P. 2247−9.
- Durig J. Differential expression of chemokine receptors in В cell malignancies. / J. Durig, U. Schmucker, U. Duhrsen // Leukemia. 2001, May. — Vol. 15, № 5.-P. 752−6.
- Effect of p53 alleles on placental weight / R. Birgander et al. // Hum. Hered. 1996, Sep-Oct. — Vol. 46, № 5. — P. 290−7.
- Effect of the codon 72 polymorphism (c.215G>C, p. Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma / Y. Wang et al. // Hum. Mutat. 2004, Jul. -Vol. 24, № 1.-P. 21−34.
- Elevated Frequency and Functional Activity of a Specific Germ-Line p53 Intron Mutation in Familial Breast Cancer / T. A. Lehman et al. // Cancer Research. 2000, Feb. — Vol. 60. — P. 1062−1069.
- Expression of chemokine receptors, CXCR4 and CXCR5, and chemoki-nes, BLC and SDF-1, in the eyes of patients with primary intraocular lymphoma /
- C. C. Chan et al. // Ophthalmology. 2003, Feb. — Vol. 110, № 2. — P. 421−6.
- Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma /
- D. Jones et al. // Blood. 2000, Jul. — Vol. 96, № 2. — P. 685−690.
- Frequent loss of p53 codon 72 Pro variant in hepatitis С virus-positive carriers with hepatocellular carcinoma / M. Anzola et al. // Cancer Lett. 2003, Apr. — Vol. 193, № 2. — P. 199−205.
- Functional analysis of the p53 protein in AIDS-related non-Hodgkin's lymphomas and polymorphic lymphoproliferations / A. Martin et al. // Br. J. Haematol. 1998, May.-Vol. 101, № 2. — P. 311−7.
- Functional analysis of the roles of posttranslational modifications at the p53 С terminus in regulating p53 stability and activity / L. Feng et al. // Mol. Cell Biol. 2005, Jul. — Vol. 25, № 13. — P. 5389−5395.
- Galvani A. P. The evolutionary history of the CCR5-Delta32 HIV-resistance mutation / A. P. Galvani, J. Novembre // Microbes Infect. 2005, Feb. -Vol. 7, № 2.-P. 302−9.
- Gene Organization and Promoter Function for CC Chemokine Receptor 5 (CCR5) / F. Guignard et al. // The Journal of Immunology 1998. — Vol. 160. -P. 985−992.
- Genetic alterations during colorectal-tumor development / B. Vogelstein et al. // N. Engl. J. Med. 1988.-Vol. 319.-P. 525−32.
- Genetic polymorphism of p53 and XRCC1 in cervical intraepithelial neoplasm in Taiwanese women / M. T. Wu et al. // J. Formos. Med. Assoc. -2004. Vol. 103. — P. 337−43.
- Genetic polymorphisms of GSTM1, p21, p53 and HPV infection with cervical cancer in Korean women / S. A. Lee et al. // Gynecol. Oncol. 2004. -Vol. 93.-P. 14−18.
- Genetic polymorphisms of XRCC1 and risk of the esophageal cancer / J. M. Lee et al. // Int. J. Cancer. 2001. — Vol. 95. — P. 240−246.
- Genetic regulation of ionizing radiation sensitivity and breast cancer risk / J. J. Hu et al. // Environ. Mol. Mutagen. 2002. — Vol. 39, № 2−3. — P. 208−15.
- Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene / M. Dean et al. // Science. 1996. -Vol. 273.-P. 1856−1862.
- Genetic variation at the chemokine receptors CCR5/CCR2 in myocardial infarction / P. Gonzalez et al. // Genes. Immun. 2001. — Vol. 2. — P. 191— 195.
- Genomic aberrations and survival in chronic lymphocytic leukemia / H. Dohner et al. // New Engl. J. Medicine. 2000, Dec. — Vol. 343, № 26. — P. 1910−1916.
- Genotype and allele frequency of a 32-base pair deletion mutation in the CCR5 gene in various ethnic groups: absence of mutation among Asians and Pacific Islanders / Y. Lu et al. // Int. J. Infect. Dis. -1999, Sum. Vol. 3, № 4. — P. 186−91.
- Germn line p53 mutations in a familial symdrome of breast cancers, sarcomas, and other neoplasms / P. Malkin et al. // Science. 1990. — Vol. 250. — P. 1233−1238.
- Germn line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome / S. Srivastava et al. // Nature. 1990. — Vol. 348. -P. 747−749.
- Goedert J. J. The epidemiology of acquired immunodeficiency syndrome malignancies / J. J. Goedert // Semin. Oncol. 2000, Aug. — Vol. 27, № 4. -P. 390−401.
- Hiddemann W. Oncology. The path to a pathogenesis-oriented treatment / W. Hiddemann // Dtsch. Med. Wochenschr. 1999. — Vol. 124. — P. 1562−1565
- Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype / X. Jin et al. // Carcinogenesis. 1995. — Vol. 16. — P. 22 052 208.
- HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC CKR-5 / T. Dragic et al. // Nature. 1996. — Vol. 381. — P. 667−673.
- Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection / R. Liu et al. // Cell.1996.-Vol. 86.-P. 367−377.
- HPV16/18 prevalence in cervical lesions/cancers and p53 genotypes in cervical cancer patients from India / D. Saranath et al. // Gynecol. Oncol. -2002.-Vol. 86.-P. 157−62.
- HPV-related cancer susceptibility and p53 codon 72 polymorphism / A. C. Gustafsson et al. // Acta. Dermatol. Venereol. 2001. — Vol. 81. — P. 125−9.
- Hu Y. The p53 Codon 72 Proline Allele Is Associated with p53 Gene Mutations in Non-Small Cell Lung Cancer / Y. Hu, M. P. McDermott, A. S. Ahrendt // Clinical Cancer Research. 2005. Apr. — Vol. 11. — P. 2502−2509.
- Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression / R. Salcedo et al. // Blood. 2000. — Vol. 96. — P. 34−40.
- IARC p53 mutation database: a relational database to compile and analyze p53 mutations in human tumors and cell lines. International Agency for Research on Cancer / T. Hernandez-Boussard et al. // Hum. Mutat. 1999. — Vol. 14, № l.-P. 1−8.
- Identification of a major co-receptor for primary isolates of HIV-1 / H. Deng et al. // Nature. 1996. — Vol. 381. — P. 661−666.
- Imyanitov E. N. Searching for cancer-associated gene polymorphisms: promises and obstacles / E. N. Imyanitov, A. V. Togo, K. P. Hanson // Cancer Lett. 2004. — Vol. 204. — P. 3−14.
- Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants / M. Tada et al. // Cancerogenesis. 2001, Mar. — Vol. 22, № 3.-P. 515−7.
- Inactivation of the ARF-MDM-2-p53 pathway in sporadic Burkitt’s lymphoma in children / M. Wilda et al. // Leukemia. 2004, Mar. — Vol. 18, № 3.-P. 584−8.
- Influence of nucleotide polymorphisms in the CCR2 gene and the CCR5 promoter on the expression of cell surface CCR5 and CXCR4 / B. Shieh et al. // Int. Immunol. 2000, Sep. — Vol. 12, № 9. — P. 1311−8.
- Influence of polymorphism at p53, CYP1A1 and GSTM1 loci on p53 mutation and association of p53 mutation with prognosis in lung cancer / Y. C.
- Wang et al. // Zhonghua Yi Xue Za Zhi (Taipei). 1999, Jul. — Vol. 62, № 7. -P. 402−10.
- Inheritance of the 194Trp and the 399Gln variant alleles of the DNA repair gene XRCC1 are associated with increased risk of early-onset colorectal carcinoma in Egypt / S. Z. Abdel-Rahman et al. // Cancer Lett. 2000. — Vol. 159. -P. 79−86.
- Integration status of virus DNA and p53 codon 72 polymorphism in human papillomavirus type 16 positive cervical cancers / K. Szarka et al. // Anticancer Res. 2000. — Vol. 20. — P. 2161−7.
- Interferon-alpha and p53 alleles involved in nasopharyngeal carcinoma / I. Golovleva et al. // Carcinogenesis. 1997. — № 18. — P. 645−647.
- International Union of pharmacology. XXII. Nomenclature for chemokine receptors / P. M. Murphy et al. // Pharm. Rev. 2000, Mar. — Vol. 52, № l.-P. 145−176.
- Intron 3 16 bp duplication polymorphism of p53 is associated with an increased risk for breast cancer by the age of 50 years / S. Wang-Gohrke et al. // Pharmacogenetics. 2002, Apr. — Vol. 12, № 3. — P. 269−72.
- Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations / S. Wang-Gohrke et al. // Br. J. Cancer. 1999, Sep. — Vol. 81, № 1. — P. 179−83.
- Involvement of poly (ADP-ribose) polymerase in base excision repair / F. Dantzer et al. //Biochimie. 1999. — Vol. 81. — P. 69−75.
- Is spatial distribution of the HIV-1-resistant CCR5Delta32 allele formed by ecological factors? / O. Balanovsky et al. // J. Physiol. Anthropol. Appl. Human. Sci. 2005, Jul. — Vol. 24, № 4. — P. 375−82.
- Jackson S. P. Sensing and repairing DNA double-strand breaks / S. P. Jackson // Carcinogenesis. 2002, May. — Vol. 23, № 5. — P. 687−696.
- Juven-Gershon T. Mdm2: the ups and downs / T. Juven-Gershon, M. Oren // Mol. Med. 1999. — Vol. 5. — P. 71−83.
- Kelsey J. L. Epidemiology and prevention of breast cancer / J. L. Kel-sey, L. Berstein // Annu. Rev. Public Health. 1996. — Vol. 17. -P. 47−67.
- Koushik A. p53 codon 72 polymorphism and cervical neoplasia: a metaanalysis review / A. Koushik, R. W. Piatt, E. L. Franco // Cancer Epidemiol. Biomarkers Prev. 2004. — Vol.'13. — P. 11−22.
- Kuzminov A. Single-strand interruptions in replicating chromosomes cause double-strand breaks / A. Kuzminov // Natl. Acad. Sci. USA. 2001. — Vol. 98.-P. 8241−8246.
- Laden F. Environmental risk factors and female breast cancer / F. Laden, D. J. Hunter // Annu. Rev. Public Health. 1998. — Vol. 19. — P. 101−123.
- Land С. E. Studies of cancer and radiation dose among atomic bomb survivors. The example of breast cancer / С. E. Land // J. Am. Med. Assoc. 1995. -Vol. 274.-P. 402−407.
- Large-cell variants of mantle cell lymphoma: cytologic characteristics and p53 anomalies may predict poor outcome / M. C. Zoldan et al. // Br. J. Haematol. 1996, May. — Vol. 93, № 2. — P. 475−86.
- Li-Fraumeni syndrome: a molecular and clinical review / J. M. Varley et al. // Br. J. Cancer. 1997. — Vol. 76. — P. 1−14.
- Lindahl T. Instability and decay of the primary structure of DNA / T. Lindahl //Nature. 1993. — Vol. 362. — P. 709−715.
- Luther S. A. Chemokines as regulators of T cell differentiation / S. A. Luther, J. G. Cyster // Nat. Immunol. 2001. — Vol. 2. — P. 102−7.
- Mahasneh A. A. Polymorphism of p53 gene in Jordanian population and possible associations with breast cancer and lung adenocarcinoma / A. A. Mahasneh, S. S. Abdel-Hafiz // Saudi Med. J. 2004, Nov. — Vol. 25, № 11. — p. 156 873.
- Malkin D. p53 and the Li-Fraumeni syndrome / D. Malkin // Biochim. Biophys. Acta. 1994. — Vol. 1198.-P. 197−213.
- Malkinson A. M. The intronic structure of cancer-related genes regulates susceptibility to cancer / A. M. Malkinson, M. You // Mol. Carcinog. 1994, Jun. — Vol. 10, № 2.-P. 61−5.
- Mattick J. S. Introns: evolution and function / J. S. Mattick // Cuit. Opin. Genet. Dev. 1994, Dec. — Vol. 4, № 6. — P. 823−31.
- Mechanism of Transdominant Inhibition of CCR5-mediated HIV-1 Infection by ccr5Delta32 / M. Benkirane et al. // JBC. 1997, Dec. — Vol. 272. -P. 30 603−30 606.
- Membrane raft microdomains mediate front-rear polarity in migrating cells / S. Manes et al. // EMBO J. 1999. — Vol. 18. — P.6211−6220.
- Molecular analysis of cutaneus B- and T-cell lymphomas / A. Neri et al. // Blood. 1995, Oct. — Vol. 86, № 8. — P. 3160−72.
- Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MlP-lalpha, and MIP-1 / C. J. Raport et al. // J. Biol. Chem. 1996. — Vol. 271.-P. 17 161−17 166.
- Molecular cloning and functional expression of a new human CC-chemokine receptor gene / M. Samson et al. // Biochemistry. 1996. — Vol. 35. -P. 3362−3367.
- Molecular features of primary mediastinal B-cell lymphoma: involvement of pl6INK4A, p53 and c-myc / A. Scorpa et al. // Br. J. Haematol. 1999, Oct.-Vol. 107, № l.-P. 106−13.
- Murphy P. M. Chemokines and molecular basis of cancer metastasis / P. M. Murphy // New Engl. J. Med. 2001, Sep. — Vol. 11, № 345. — P. 833−835.
- Mutation of a BRCT domain selectively disrupts DNA single-strand break repair in noncycling Chinese hamster ovary cells / D. J. Moore et al. // Proc. Natl. Acad. Sci. USA 2000. — Vol. 97. — P. 13 649−13 654.
- Mutations in the p53 gene occur in diverse human tumour types / J. M. Nigro et al. //Nature. 1989. — Vol. 342. — P. 705−8.
- Mutations of p53 gene and their relation to disease progression in В-cell lymphoma / A. Ichikawa et al. // Blood. 1992. — Vol. 79. — P. 2701.
- Nagpal J. K. p53 codon 72 polymorphism and susceptibility to development of human papilloma virus-associated cervical cancer in Indian women / J. K. Nagpal, S. Sahni, B. R. Das // Eur. J. Clin. Invest. 2002. — Vol. 32. — P. 9438.
- New approaches to understanding p53 gene tumor mutation spectra / M. Hollstein et al. // Mutat. Res. 1999. — Vol. 31. — P. 199−209.
- No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients / I. Mabrouk et al. // Ann. N. Y. Acad. Sci. 2003, Dec. — Vol. 1010. — P. 764−70.
- No evidence of p53 allele-specific predisposition in human papillomavi-rus-associated cervical cancer / R. Klaes et al. // J. Mol. Med. 1999. — Vol. 77. -P. 299−302.
- Novembre J. The Geographic Spread of the CCR5 DELTA.32 HIV-Resistance Allele / J. Novembre, A. P. Galvani, M. Slatkin // PLoS Biol. 2005, Nov. — Vol. 3, № 11.-P. e339.
- Oba Y. MIP-1 alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells / y. Oba, J. W. Lee, L. A. Ehrlich // Exp. Hematol. 2005, Mar. — Vol. 33, № 3. — P. 272−8.
- Palmer J. Cigarette smoking and breast cancer / J. Palmer, L. Rosenberg // Epidemiol. Rev. 1993. — Vol. 15. — P. 145−162.
- PARP-2, a novel mammalian DNA damage-dependent poly (ADP-ribose) polymerase / J. C. Ame et al. // J. Biol. Chem. 1999. — Vol. 274. — P. 17 860−17 868.
- Peripheral blood-derived CD34+ progenitor cells: CXC chemokine receptor 4 and CC chemokine receptor 5 expression and infection by HIV / M. E. Ruiz et al. // J. Immunol. 1998. — Vol. 161. — P. 4169−4176.
- Polymorphism in DNA repair genes and oral squamous cell carcinoma in Thailand / S. Kietthubthew et al. // Int. J. Hyg. Environ. Health. 2006, Jan. -Vol. 209, № 1.-P. 21−9.
- Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo / A. Sallivan et al. // Oncogene. 2004, Apr. — Vol. 23, № 19. -P. 3328−37.
- Polymorphism of the р53 codon 72 Arg/Pro and the risk of HPV type 16/18-associated cervical and oral cancer in India / S. Katiyar et al. // Mol. Cell. Biochem. 2003. — Vol. 252. — P. 117−24.
- Polymorphisms and mutations found in the regions flanking exons 5 to 8 of the TP53 gene in a population at high risk for esophageal cancer in South Africa / M. Vos et al. // Cancer Genet. Cytogenet. 2003, Jan. — Vol. 140, № 1. -P. 23−30.
- Polymorphisms in the DNA repair gene XRCC1 and breast cancer / E. J. Duell et al. // Cancer Epidemiol. Biomarkers Prev. 2001. — Vol. 10. — P. 217 222.
- Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells / E. J. Duell et al. // Carcinogenesis. 2000, May. — Vol. 21, № 5. — P. 965−71.
- Polymorphisms in the p53 gene in thyroid tumours and blood samples of children from areas in Belarus / S. Hillebrandt et al. // Mutat. Res. 1997, Nov. -Vol. 381, № 2.-P. 201−7.
- Polymorphisms in XPD and TP53 and mutation in human lung cancer / L. E. Mechanic et al. // Carcinogenesis. 2005, Mar. — Vol. 26, № 3. — P. 597 604.
- Polymorphisms of DNA repair gene XRCC1 in squamous cell carcinoma of the head and neck / E. M. Sturgis et al. // Carcinogenesis. 1999. — Vol. 20.-P. 2125−2129.
- Polymorphisms of the DNA repair gene XRCC1 and risk of gastric cancer in a Chinese population / H. Shen et al. // Int. J. Cancer. 2000. — Vol. 88. -P. 601−606.
- Polymorphisms of the XRCC1, XRCC3 and XPD genes and risk of colorectal adenoma and carcinoma, in a Norwegian cohort: a case control study / C. F. Skjelbred et al. // BMC Cancer. 2006, Mar. — Vol. 6. — P. 67.
- Polymorphisms of XRCC1 gene, alcohol consumption and colorectal cancer / Y. C. Hong et al. // Int. J. Cancer. 2005, Sep. — Vol. 116, № 3. — P. 428−32.
- Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus / L. A. Brooks et al. // Cancer Res. 2000, Dec. — Vol. 60, № 24. — P. 6875−7.
- Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers / K. Angelopoulou et al. // Int. J. Cancer. 1994, Aug. -Vol. 58, № 4.-P. 480−7.
- Prognostic significance of p53 codon 72 polymorphism in lung carcinomas / Y. C. Wang et al. // Eur. J. Cancer. 1999, Feb. — Vol. 35, № 2. — P. 226−30.
- Prognostic value of TP53 codon 72 polymorphism in advanced gastric adenocarcinoma / Z. W. Zhang et al. // Clin. Cancer Res. 2004, Jan. — Vol. 10 (1 Pt 1).-P. 131−5.
- Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations / T. Soussi et al. // Hum. Mu-tat. 2005, Jan. — Vol. 25, № 1. — P. 6−17.
- Reduced risk of AIDS lymphoma in individuals heterozygous for the CCR5-delta32 mutation / M. Dean et al. // Cancer Res. 1999, Aug. — Vol. 59, № 15.-P. 3561−4.
- Regulation of Human p53 Activity and Cell Localization by Alternative Splicing / A. Ghosh et al. // Mol. Cell Biol. 2004, Sep. — Vol. 24, № 18. — P. 7987−7997.
- Relationship of H-ras-1, L-myc, and p53 polymorphisms with lung cancer risk and prognosis / A. Weston et al. // Environ. Health Perspect. — 1992, Nov.-Vol. 98.-P. 61−67.
- Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas / W. H. Wilson et al. // Blood. 1997, Jun. -Vol. 89, № 2.-P. 601−609.
- Relationships of TP53 Codon 72 and HRAS1 Polymorphisms with Lung Cancer Risk in an Ethnically Diverse Population / L. M. Pierce et al. // Cancer Epidemiology Biomarkers & Prevention 2000, Nov. — Vol. 9. — P. 1199−1204.
- Requirement for the Xrccl DNA base excision repair gene during early mouse development / R. S. Tebbs et al. // Dev. Biol. 1999, Apr. — Vol. 208, № 2.-P. 513−29.
- Resistance to HIV-l infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene / M. Samson et al. // Nature (Lond). 1996. — Vol. 382. — P. 722−725.
- Response of cell cycle proteins to neurotrophic factor .and chemokine stimulation in human neuroglia /К. Jordan-Sciutto et al. // Exp. Neurol. 2001. -Vol. 167.-P. 205−214.
- Risk assessment of p53 genotypes and haplotypes in tobacco-associated leukoplakia and oral cancer patients from eastern Idia / S. Mitra et al. // Int. J. Cancer. 2005, Dec. — Vol. 117, № 5. — P. 786−93.
- Role for macrophage inflammatory protein (MIP)-lalpha and MlP-lbeta in the development of osteolytic lesions in multiple myeloma / M. Abe et al. // Blood. 2002, Sep. — Vol. 100, № 6. — P. 2195−202.
- Role of a p53 polymorphism in the development of human papillomavi-rus-associated cancer / A. Storey et al. // Nature 1998. — Vol. 393. — P. 229−34.
- Role of the p53 tumor suppressor gene in cell cycle arrest and radiosen-sitivity of Burkitt’s lymphoma cell lines / P. M. O’Connor et al. // Cancer Res. -1993.-Vol. 53.-P. 4776.
- Sakurai E. Macrophage depletion inhibits experimental choroidal neovascularization / E. Sakurai, A. Anand, В. K. Ambati // Cancer Res. 2002. -Vol. 62.-P. 1093−102.
- Selective infiltration of CCR5(+)CXCR3(+) T lymphocytes in human colorectal carcinoma / H. Musha et al. // Int. J. Cancer. 2005, Oct. — Vol. 116, № 6.-P. 949−56. I
- Shen M. R. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans / M. R. Shen, I. M. Jones, H. Mohrenweiser // Cancer Res. 1998. — Vol. 58. — P. 604−608.
- Shipp M. A. International Non-Hodgkins lymphoma prognostic factors project. A predictive model for agressive non-Hodgkins lympoma / M. A. Shipp // N. Engl. J. Med. 1993. — Vol. 329. — P. 987−94.
- Simple sequence repeat polymorphism within the p53 gene / V. Lazar et al. // Oncogene/ 1993.-Vol. 8.-P. 1703−1705.
- Single base polymorphism in the human tumor necrosis factor alpha (TNF alpha) gene detectable by Ncol restriction of PCR product / A. G. Wilson et al. // Hum. Mol. Genet. 1992. — Vol. 1. — P. 353.
- Taylor R. M. Central Role for the XRCC1 BRCTI Domain in Mammalian DNA Single-Strand Break Repair / R. M. Taylor, A. Thistlethwaite, K. W. Caldecott // Mol. Cell. Biol. 2002, Apr. — Vol. 22, № 8. — P. 2556−2563.
- Tebbs R. S. Rescue of Xrccl knockout mouse embryo lethality by transgene-complementation / R. C. Tebbs, L. H. Thompson, J. E. Cleaver // DNA Repair (Amst). 2003, Dec. — Vol. 2, № 12. — P. 1405−17.
- Testis and somatic Xrcc-1 DNA repair gene expression / C. A. Walter et al. // Somat. Cell. Mol. Genet. 1994, Nov. — Vol. 20, № 6. — P. 451−61.
- Thl, Th2, and activated T-cell marker and clinical prognosis in peripheral T-cell lymphoma, unspecified: comparison with AILD, ALCL, lymphoblastic lymphoma, and ATLL / T. Tsuchiya et al. // Blood. 2004, Jan. — Vol. 103, № l.-P. 236−41.
- The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV isolates / H. Choe et al. // Cell. 1996. — Vol. 85. — P. 1135−1148.
- The case for selection at CCR5-Delta32 / P. C. Sabeti at al. // PLoS Biol. 2005, Nov. — Vol. 3, № 11. — P. e378.
- The CC chemokine rantes in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity / E. Azenshtein et al. // Bioorg. Med. Chem. 2003. — Vol. 11. — P. 2663−76.
- The CC-chemokine receptor 5 (CCR5) is a marker of, but not essential for the development of human Thl cells / N. Odum et al. // Tissue Antigens. -1999, Dec/ Vol. 54, № 6. — P. 572−7.
- The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice / U. Mrowietz et al. // Br. J. Cancer. 1999. — Vol. 79. — P. 1025−31.
- The codon 72 polymorphic variants of p53 have markedly different apoptotic potential / P. Dumont et al. // Nat. Genet. 2003, Mar. — Vol. 33, № 3. -P. 357−65.
- The delta32 deletion of CCR5 receptor in rheumatoid arthritis / S. Cooke et al. //Arthritis Rheum. 1998. — Vol. 41. — P. 1135−1136.
- The different apoptotic potential of the p53 codon 72 alleles increases with age and modulates in vivo ischaemia-induced cell death / M. Bonafe et al. // Cell Death Differ. 2004, Sep. — Vol. 11, № 9. — P. 962−73.
- The frequency of mutation in CCR5 gene among Koreans / M. D. Oh et al. // Int. J. STD AIDS. 2000, Apr. — Vol. 11, № 4. — P. 266−7.
- The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes / С. C. Bleul et al. // Proc. Natl. Acad. Sci. USA. 1997. — Vol. 94. — P. 1925−1930.
- The MDM2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation / J. Momand et al. // Cell. 1992. -Vol. 691.-P. 1237−45.
- The p53 codon 72 genotypes in HPV infection and cervical disease / M. C. Abba et al. // Eur. J. Obstet. Gynecol. Reprod. Biol. 2003. — Vol. 109. — P. 63−6.
- The role of a mutant CCR5 allele in HIV-l transmission and disease progression / Y. Huang et al. // J. Immunol. 1996. — Vol. 163. — P. 4642−4646.
- The role of XRCC 1 polymorphisms in base excision repair of etheno-DNA adducts in French vinyl chloride workers / Y. Li et al. // Int. J. Occup. Med. Environ. Health. 2006. — Vol. 19, № 1. — P. 45−52.
- The transcription of the XRCC1 gene in the heart of radiation-resistant and radiation-sensitive mice after ionizing irradiation / O. Labudova et al. // Pe-diatr. Res. 1997, Mar. — Vol. 41, № 3. — P. 435−9.
- The XRCC1 399 glutamine allele is a risk factor for adenocarcinoma of the lung / К. K. Divine et al. // Mutat. Res. 2001. — Vol. 461. — P. 273−278.
- The XRCC1 -77T" border=0 src=7math/large/rarr.gif'C variant: haplotypes, breast cancer risk, response to radiotherapy and the cellular response to DNA damage / R. Brem et al. // Carcinogenesis. 2006. — Vol. 27, № 12. — P. 2469−2474.
- Thiagalingam S. A. Cascade of modules of a network defines cancer progression 11 S. A. Thiagalingam 11 Cancer Res. 2006. — Vol. 66, № 15. — P. 7379−85.
- TP53 intron 6 polymorphism and the risk of ovarian and breast cancer / D. Mavridou et al. // Br. J. Cancer. 1998, Feb. — Vol. 77, № 4. — P. 676−7.
- TP53 mutation, allelism and survival in non-small cell lung cancer / H. H. Nelson et al. // Carcinogenesis. 2005. — Vol. 26, № 10. — P. 1770−1773.
- TP53 polymorphism at exon 4 in Caucasian women from eastern France: lack of correlation with HPV status and grade of cervical precancerous lesions / O. Humbey et al. // Eur. J. Obstet. Gynecol. Reprod. Biol. 2002. — Vol. 103.-P. 60−4.
- Weston A. True extended haplotypes of p53: indicators of breast cancer risk / A. Weston, M. S. Wolff, A. Morabia // Cancer Genet. Cytogenet. 1998. -Vol. 102.-P. 153−4.
- Weston A. Polymorphisms of HRAS-1 and p53 in breast cancer and lung cancer: a meta-analysis / A. Weston, J. H. Godbold // Environ. Health Per-spect. 1997. — Vol. 105(S4). — P. 919−926.
- Weston A. Allelic frequency of a p53 polymorphism in human lung cancer / A. Weston, L. S. Perrin, K. Forrester // Cancer Epidemiol. Biomark. Prev. -1992.-Vol. 1.-P. 481−483.
- Wong S. Chemokine receptor expression in B-cell lymphoproliferative disorders / S. Wong, D. Fulcher // Leuk. Lymphoma. 2004, Dec. — Vol. 45, № 12.-P. 2491−6.
- World Health Organization Classification of tumours. Pathology and genetics of tumours of hemopoietic and lymphoid tissues / E. S. Jaffe et al. -Lyon: IACR Press: Lyon, 2001.
- Xrcc-1 expression during male meiosis in the mouse / C. A. Walter et al. // Bbiol. Reprod. 1996, Sep. — Vol. 55, № 3. — P. 630−5.
- XRCC1 genotype and non-melanoma skin cancer: results from a case-control study / H. H. Nelson et al. // Proc. Am. Assoc. Cancer Res. 2000. -Vol. 41.-P. 437.
- XRCC1 polymorphisms (Argl94Trp and Arg399Gln) and risk for head and neck cancer / M. A. Watson et al. // Abstract No. 3551, Proc. Am. Assoc. Cancer Res. 2000. — Vol. 41. — P. 557.
- XRCC1 polymorphisms: effects on aflatoxin B-l-DNA adducts and gly-cophorin A variant frequency / R. M. Lunn et al. // Cancer Res. 1999. — Vol. 59.-P. 2557−2561.
- XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects / G. Matullo et al. // Carcinogenesis. -2001.-Vol. 22.-P. 1437−1445.
- Zhang W. Polymorphism at codon 72 of the p53 gene in human acute myelogenous leukemia / W. Zhang, G. Hu, A. Deisseroth // Gene. 1992. — Vol. 117.-P. 271−275.
- Zhang Y. Control of p53 Ubiquitination and Nuclear Export by MDM2 and ARF / Y. Zhang, Y. Xiong // Cell Growth & Differentiation. 2001, Apr. -Vol. 12.-P. 175−186.